Another recently published retrospective study by Livanainen et al. investigated the prognostic role of pretreatment CRP levels in a mixed cohort of NSCLC, metastatic melanoma, renal and bladder cancer patients treated with anti- PD-(L)-1 agents. Here, CRP is linked to urinary bladder carcinoma.